Loading
A phase 1/2 trial of TBI-1501 in acute lymphoblastic leukaemia, run by Takara Bio Inc., active and no longer recruiting.
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT03155191 by Takara Bio Inc., with 21 participants enrolled, started 2017-06-01 and due to reach its primary completion in 2035-03-31. Interventions recorded: TBI-1501.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Takara Bio and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/